3 Australian AI Healthcare Stocks Investors Are Watching Closely

AI healthcare stocks sit at the crossroads of two major forces investors are watching right now. On one side, you have central banks weighing interest rate paths as inflation, energy costs, and wages move in different directions across regions. On the other, AI tools are being applied to diagnostics, hospital operations, and drug discovery to improve accuracy and reduce waste. The Transformative AI Healthcare Stocks screener filters this broad story into a focused set of companies that are using AI in practical ways. This article highlights 3 stocks from that screener that many investors are watching closely.

ImExHS (ASX:IME)

Overview: ImExHS is a Sydney based healthcare software company that provides cloud-based imaging platforms for radiology, cardiology, and pathology, alongside outsourced and teleradiology services for hospitals and clinics in multiple countries.

Operations: ImExHS generates about A$10.0 million from Software and A$19.2 million from Radiology, with total revenue of around A$29.0 million primarily from Latin America.

Market Cap: A$16.5 million

ImExHS catches investor attention because it combines a cloud-native imaging platform with in-house radiology operations, so every scan can feed both revenue and data for its AI tools. The company is targeting higher earnings and improved margins as more work moves through its Aquila+ platform and higher value contracts come through partners in 12 countries. At the same time, the company is still loss-making, heavily tied to Latin American health systems, and funded entirely by external borrowing, which raises questions about balance sheet resilience. A new CFO and changes in the finance function add another layer of uncertainty. That mix of potential growth and real execution risk is what may make ImExHS worth a closer look for AI healthcare investors.

ImExHS is trying to turn every scan into both revenue and training data, yet the real story lies in how its funding, margins, and contracts fit together in one place. Read the 2 key rewards and 1 important warning sign

Singular Health Group (ASX:SHG)

Overview: Singular Health Group is an Australian medical technology company that turns standard 2D medical scans into interactive 3D models. This helps doctors and patients better visualise anatomy for diagnosis, treatment planning, and surgery preparation, while also offering tools for secure image sharing and AI assisted analysis.

Operations: Singular Health Group generates around A$1.0 million in revenue from the provision and development of medical technology, including A$0.52 million from the United States.

Market Cap: A$60.2 million

Singular Health Group attracts attention because it sits at the intersection of 3D visualisation and AI imaging, turning complex scan data into clearer pictures that can support clinical decisions. The stock is still highly speculative, with revenue under A$1.0 million, ongoing losses, a return on equity of roughly 64% in the red, and less than one year of cash runway, which keeps funding risk front and centre. Its focus on AI in the cloud, partnerships with healthcare providers, and progress toward regulatory clearances gives it exposure to some closely watched use cases in AI healthcare. That combination of product potential, valuation questions around a 5.1x P/B ratio, and a thin financial cushion makes Singular Health Group a higher risk idea that some investors still follow closely.

Singular Health Group’s tiny revenue base and 5.1x P/B ratio raise big questions about what investors think comes next. For more details, see the analysis report for Singular Health Group

Artrya (ASX:AYA)

Overview: Artrya is an Australian medical technology company that develops AI powered, cloud based cardiac imaging software called Salix. The software reads coronary CT angiography scans to detect coronary artery disease and help clinicians identify patients at risk of a heart attack.

Operations: Artrya currently generates around A$0.03 million in revenue from the development of its AI driven CCTA image analysis technology in Australia.

Market Cap: A$656.8 million

Artrya attracts attention because it is aiming to turn the growing use of coronary CT scans into a scalable, AI based fee per scan business. It is backed by a cash position of about A$76.5 million and no debt. At the same time, revenue remains very small, losses are significant, and the commercial story depends heavily on future US scan volumes, regulatory progress for the Salix Flow module, and the large SAPPHIRE trial delivering convincing data. Analysts currently expect very high growth, a new CFO has joined from Pro Medicus, and the company has meaningful funding capacity. Investors watching AI healthcare may see Artrya as a high potential but execution heavy story that is worth monitoring closely.

Artrya’s large market cap, tiny revenue and sizeable cash balance suggest many investors may be overlooking important details about its potential growth. Get the full context in the analyst forecasts for Artrya

The three AI healthcare stocks in this article are just a starting point, as the full Transformative Artificial intelligence (AI) Healthcare Stocks screener surfaces 5 more companies with equally compelling AI healthcare narratives that many investors may not have on their radar yet. Use Simply Wall St to identify and analyze the specific AI catalysts, clinical milestones, and funding profiles that matter most to you so you can focus on the highest conviction opportunities in this space.

Take Control of Your Investment Journey

If ImExHS or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives With Real Curiosity

New themes can move from quiet to breakout before most investors notice. Consider fresh stock ideas while the data is still under the radar and take action based on your own research and judgment.

• Target resilient cash generators before momentum takes off by scanning the curated 8 high quality undervalued stocks that balance robust cash flows with disciplined balance sheets.
• Consider structural demand for critical materials by reviewing the hand picked 28 best rare earth metal stocks shaping next generation energy, electronics, and advanced manufacturing.
• Explore infrastructure and electrification trends by checking the focused 36 power grid technology and infrastructure stocks supporting grid upgrades, reliability, and future power demand.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com